नाइजीरिया - अंग्रेज़ी - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin 200mg,clavulanic acid 28mg - dafraclav® is indicated in the treatment of the following in­fections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

नाइजीरिया - अंग्रेज़ी - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - film coated tablets - amoxicillin 875mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

नाइजीरिया - अंग्रेज़ी - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - amoxicillin + clavulanic acid - amoxicillin 400mg,clavulanic acid 57mg - dafraclav is indicated in the treatment of the following infections caused by the microorganisms indicated below. - upper respiratory tract infections (including otitis media and sinusitis), due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - lower respiratory tract infections, due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. - skin and skin structure infections, due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. - urinary tract infections. since dafraclav contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav, such an infection can be treated by the administration of dafraclav alone, addition of another antibiotic is not required.

तंज़ानिया - अंग्रेज़ी - Tanzania Medicinces & Medical Devices Authority

dafra pharma gmbh, switzerland - amoxicillin , clavulanic acid - suspension, oral - 228

तंज़ानिया - अंग्रेज़ी - Tanzania Medicinces & Medical Devices Authority

dafra pharma gmbh, switzerland - amoxicillin , clavulanic acid - tablet, film-coated - 875 mg

नाइजीरिया - अंग्रेज़ी - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - tablets - amoxillin 500mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

तंज़ानिया - अंग्रेज़ी - Tanzania Medicinces & Medical Devices Authority

dafra pharma gmbh, switzerland - amoxicillin , clavulanic acid - tablet, film-coated - 625

तंज़ानिया - अंग्रेज़ी - Tanzania Medicinces & Medical Devices Authority

dafra pharma gmbh, switzerland - omeprazole - powder and solvent for solution for injection - 40

केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

dafra pharma gmbh weidboden 271 4618 boningen switzerland - amoxicillin clavulanic acid - tablet - amoxicillin 875mg + clavulanic acid 125 mg - beta-lactamantibacterials: combinations of

केन्या - अंग्रेज़ी - Pharmacy and Poisons Board

dafra pharma gmbh weidboden 2714618 boningenswitzerland - amoxicillin clavulanic acid - powder for oral suspension - amoxicillin 200mg + clavulanic acid 28 mg - beta-lactamantibacterials: combinations of